Should I buy or sell Sensei Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares. View SNSE analyst ratings or view top-rated stocks .

What is Sensei Biotherapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for Sensei Biotherapeutics' shares. Their SNSE share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 459.4% from the stock's current price. View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts .

How have SNSE shares performed in 2023?

Sensei Biotherapeutics' stock was trading at $1.49 on January 1st, 2023. Since then, SNSE shares have decreased by 52.0% and is now trading at $0.7150. View the best growth stocks for 2023 here .

Are investors shorting Sensei Biotherapeutics?

Sensei Biotherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 168,800 shares, an increase of 25.6% from the October 31st total of 134,400 shares. Based on an average daily volume of 47,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.0% of the shares of the company are sold short. View Sensei Biotherapeutics' Short Interest .

When is Sensei Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our SNSE earnings forecast .

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its earnings results on Tuesday, November, 7th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28).

When did Sensei Biotherapeutics IPO?

(SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

Who are Sensei Biotherapeutics' major shareholders?

Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (7.20%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer , John Celebi, Robert Hamilton Pierce and Thomas G Ricks . View institutional ownership trends .

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sensei Biotherapeutics Stock Price, News & Analysis (NASDAQ:SNSE)

$0.72

+0.04 (+5.93%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.68
▼
$0.77
50-Day Range: $0.53
▼
$0.82
52-Week Range: $0.51
▼
$1.93

Volume: 55,868 shs
Average Volume: 48,111 shs
Market Capitalization: $17.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Sensei Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 459.4% Upside
$4.00 Price Target
Short Interest: Healthy
1.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.38
Upright™ Environmental Score
News Sentiment: 0.00
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$425 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.24) to ($1.00) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

90th out of 948 stocks

Pharmaceutical Preparations Industry

26th out of 421 stocks

3.5

Analyst's Opinion

Consensus Rating
Sensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Sensei Biotherapeutics has a forecasted upside of 459.4% from its current price of $0.72.
Amount of Analyst Coverage
Sensei Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.01% of the float of Sensei Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sensei Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sensei Biotherapeutics has recently increased by 25.60%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sensei Biotherapeutics does not currently pay a dividend.
Dividend Growth
Sensei Biotherapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sensei Biotherapeutics is -0.38.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 4 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sensei Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $425.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
25.50% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.52% of the stock of Sensei Biotherapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($1.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sensei Biotherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sensei Biotherapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sensei Biotherapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sensei Biotherapeutics Stock (NASDAQ:SNSE)

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

SNSE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNSE Stock News Headlines

December 5, 2023 | americanbankingnews.com

Sensei Biotherapeutics (NASDAQ:SNSE) Receives New Coverage from Analysts at HC Wainwright

December 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 4, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy Recommendation

November 7, 2023 | msn.com

Sensei Biotherapeutics GAAP EPS of -$0.28 in-line

November 7, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 7, 2023 | finance.yahoo.com

Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results

November 3, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 25, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

October 24, 2023 | bizjournals.com

Rockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from Nasdaq

October 23, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

September 27, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

September 21, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

September 13, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

August 30, 2023 | uk.finance.yahoo.com

SNSE - Sensei Biotherapeutics, Inc.

August 3, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 2, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

June 13, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”

June 1, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 31, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 10, 2023 | markets.businessinsider.com

Citigroup Remains a Buy on Sensei Biotherapeutics (SNSE)

May 9, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

April 20, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

April 18, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

April 13, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

March 30, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

See More Headlines

Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNSE
CUSIP: N/A
CIK: 1829802
Web: www.senseibio.com
Phone: 240-243-8000
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +459.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,590,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.68%
Return on Assets: -39.16%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 11.86
Quick Ratio: 11.86

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.37 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 24,997,000
Free Float: 18,623,000
Market Cap: $17.87 million
Optionable: Not Optionable
Beta: 0.01

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. John K. Celebi M.B.A. (Age 51)
President, CEO & Director
Comp: $799.69k
Ms. Erin Colgan (Age 42)
Chief Financial Officer
Comp: $558.83k
Dr. Edward Van der Horst Ph.D. (Age 50)
Chief Scientific Officer
Comp: $444.87k
Ms. Lora Pike
Vice President of Investor Relations & Communications
Mr. Christopher W. Gerry J.D.
General Counsel & Secretary
Ms. Stephanie Krebs M.B.A.
M.S., Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNSE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings or view top-rated stocks.
What is Sensei Biotherapeutics' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month target prices for Sensei Biotherapeutics' shares. Their SNSE share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 459.4% from the stock's current price.
View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts.
How have SNSE shares performed in 2023?: Sensei Biotherapeutics' stock was trading at $1.49 on January 1st, 2023. Since then, SNSE shares have decreased by 52.0% and is now trading at $0.7150.
View the best growth stocks for 2023 here.
Are investors shorting Sensei Biotherapeutics?: Sensei Biotherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 168,800 shares, an increase of 25.6% from the October 31st total of 134,400 shares. Based on an average daily volume of 47,200 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.0% of the shares of the company are sold short.
View Sensei Biotherapeutics' Short Interest.
When is Sensei Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our SNSE earnings forecast.

How were Sensei Biotherapeutics' earnings last quarter?: Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its earnings results on Tuesday, November, 7th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28).
When did Sensei Biotherapeutics IPO?: (SNSE) raised $100 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.
Who are Sensei Biotherapeutics' major shareholders?: Sensei Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Newtyn Management LLC (7.20%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, John Celebi, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends.
How do I buy shares of Sensei Biotherapeutics?: Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNSE) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial